Features of the clinical course of the disease, quality of life and cytokine profile in patients with true eczema in the chronic stage and depression

Abstract

BACKGROUND: The relationship between true eczema in the chronic stage and depression is currently of exceptional scientific interest.

AIM: To study of the features of the clinical course of the disease, quality of life and cytokine profile in patients with true eczema in the chronic stage and depression.

MATERIALS AND METHODS: A prospective cross-sectional comparative study involved 157 patients (86 men and 71 women) aged 18 to 40 years (average 31.2 [29.7; 35.6]) with true eczema in the chronic stage; of these, two groups were formed: 66 patients with comorbid depression and 91 without comorbid depression. The Montgomery-Asberg scale was used to determine depression symptoms and severity.

RESULTS: Patients with true eczema in the chronic stage and depression were characterized by a younger age (p=0.021), a more severe course of the disease according to the EASI (p <0.001), Pruritus (p=0.014) indices, a higher frequency of relapses (p=0.012) and more low level of quality of life according to the DLQI questionnaire (p <0.001), as well as higher values of IL-6 and TNF-α in the blood serum (p=0.011; p=0.001, respectively). An inverse correlation was established between the average total value on the Montgomery-Asberg scale and the age of the patients (r=-0.62; p=0.002), a direct one ― with the average total values on the EASI indices (r=0.73; p=0.001), Pruritus (r=0.60; p <0.001), DLQI (r=0.69; p=0.001) and TNF-α (r=0.61; p=0.013).

CONCLUSION: In patients with depression, true eczema in the chronic stage is more severe and is accompanied by an increase in systemic pro-inflammatory changes and a more significant decrease in quality of life than in patients without depression. The results obtained must be taken into account when choosing a therapeutic strategy for true eczema, which will personalize treatment and increase its effectiveness.

Keywords

true eczema / depression / the quality of life / cytokine profile

References

[1] Sohn A, Frankel A, Patel RV, Goldenberg G. Eczema. Mt Sinai J Med. 2011;78(5):730–739. doi: 10.1002/msj.20289

[2] Sohn A., Frankel A., Patel R.V., Goldenberg G. Eczema // Mt Sinai J Med. 2011. Vol. 78, N 5. P. 730–739. doi: 10.1002/msj.20289

[3] Federal guidelines for the management of eczema patients. Moscow; 2015. (In Russ.)

[4] Федеральные рекомендации по ведению пациентов с экземой. Москва, 2015.

[5] Werfel T. Classification, trigger factors and course of chronic hand eczema. (In German). MMW Fortshr Med. 2009;151(19):31–34.

[6] Werfel T. Classification, trigger factors and course of chronic hand eczema. (In German) // MMW Fortshr Med. 2009. Vol. 151, N 19. P. 31–34.

[7] Stollery N. Eczema. Practitioner. 2015;259(1779):30–31.

[8] Stollery N. Eczema // Practitioner. 2015. Vol. 259, N 1779. P. 30–31.

[9] Novikova LA, Dontsova EV, Chernov AV, et al. Correction of psychoemotional disorders and quality of life in patients with eczema using janus kinase inhibitor. Med Alphabet. 2023;(5):37–41. EDN: DLOUXP doi: 10.33667/2078-5631-2023-5-37-41

[10] Новикова Л.А., Донцова Е.В., Чернов А.В., и др. Коррекция психоэмоциональных расстройств и качества жизни у больных истинной экземой с помощью ингибитора янус-киназы // Медицинский алфавит. 2023. № 5. С. 37–41. EDN: DLOUXP

[11] Bekić S, Martinek V, Talapko J, et al. Atopic dermatitis and comorbidity. Healthcare. 2020;8(2):70. EDN: TYVCVC doi: 10.3390/healthcare8020070

[12] Bekić S., Martinek V., Talapko J., et al. Atopic dermatitis and comorbidity // Healthcare. 2020. Vol. 8, N 2. P. 70. EDN: TYVCVC doi: 10.3390/healthcare8020070

[13] Talamonti M, Galluzzo M, Silvaggio D, et al. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10(6):1298. doi: 10.3390/jcm10061298

[14] Talamonti M., Galluzzo M., Silvaggio D., et al. Quality of life and psychological impact in patients with atopic dermatitis // J Clin Med. 2021. Vol. 10, N 6. P. 1298. doi: 10.3390/jcm10061298

[15] Schonmann Y, Mansfield KE, Hayes JF, et al. Atopic eczema in adulthood and risk of depression and anxiety: A population-based cohort study. J Allergy Clin Immunol Pract. 2020;8(1):248–257.e16. doi: 10.1016/j.jaip.2019.08.030

[16] Schonmann Y., Mansfield K.E., Hayes J.F., et al. Atopic eczema in adulthood and risk of depression and anxiety: A population-based cohort study // J Allergy Clin Immunol Pract. 2020. Vol. 8, N 1. P. 248–257.e16. doi: 10.1016/j.jaip.2019.08.030

[17] Fabrazzo M, Cipolla S, Signoriello S, et al. A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. Eur Psychiatry. 2021;25;64(1):e71. EDN: ETZZDB doi: 10.1192/j.eurpsy.2021.2249

[18] Fabrazzo M., Cipolla S., Signoriello S., et al. A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa // Eur Psychiatry. 2021. Vol. 64, N 1. P. e71. EDN: ETZZDB doi: 10.1192/j.eurpsy.2021.2249

[19] Sundberg I, Ramklint M, Stridsberg M, et al. Salivary melatonin in relation to depressive symptom severity in young adults. PLoS One. 2016;11(4):e0152814. doi: 10.1371/journal.pone.0152814

[20] Sundberg I., Ramklint M., Stridsberg M., et al. Salivary melatonin in relation to depressive symptom severity in young adults // PLoS One. 2016. Vol. 11, N 4. P. e0152814. doi: 10.1371/journal.pone.0152814

[21] Burchakov DI, Uspenskaya YB. Antioxidant, anti-inflammatory and sedative effects of melatonin: Results of clinical trials. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov J Neurol Psychiatry. 2017;117(4-2):67–73. EDN: ZCDQLR doi: 10.17116/jnevro20171174267-73

[22] Бурчаков Д.И., Успенская Ю.Б. Антиоксидантный, противовоспалительный и седативный эффекты мелатонина: результаты клинических исследований // Журнал неврологии и психиатрии им. С.С. Корсакова. 2017. Т. 117, № 4-2. С. 67–73. EDN: ZCDQLR doi: 10.17116/jnevro20171174267-73

[23] De Passos MA, Farias AV, Dos Antunes GR, et al. The relation between atopic dermatitis and depressive symptoms. Medicina (Ribeirao Preto, Online). 2022;55(1):1–13.

[24] De Passos M.A., Farias A.V., dos Antunes G.R, et al. The relation between atopic dermatitis and depressive symptoms // Medicina (Ribeirao Preto, Online). 2022. Vol. 55, N 1. P. 1–13.

[25] Hanifin JM, Baghoomian W, Grinich E, et al. The eczema area and severity index: A practical guide. Dermatitis. 2022;33(3):187–192. EDN: BNUYQS doi: 10.1097/DER.0000000000000895

[26] Hanifin J.M., Baghoomian W., Grinich E., et al. The eczema area and severity index: A practical guide // Dermatitis. 2022. Vol. 33, N 3. P. 187–192. EDN: BNUYQS doi: 10.1097/DER.0000000000000895

[27] Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–507. doi: 10.2340/00015555-1246

[28] Phan N.Q., Blome C., Fritz F., et al. Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus // Acta Derm Venereol. 2012. Vol. 92, N 5. P. 502–507. doi: 10.2340/00015555-1246

[29] Verweyen E, Ständer S, Kreitz K, et al. Validation of a comprehensive set of pruritus assessment instruments: The chronic pruritus tools questionnaire Pruritools. Acta Derm Venereol. 2019;99(7):657–663. doi: 10.2340/00015555-3158

[30] Verweyen E., Ständer S., Kreitz K., et al. Validation of a comprehensive set of pruritus assessment instruments: The chronic pruritus tools questionnaire Pruritools // Acta Derm Venereol. 2019. Vol. 99, N 7. P. 657–663. doi: 10.2340/00015555-3158

[31] Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi: 10.1192/bjp.134.4.382

[32] Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change // Br J Psychiatry. 1979. Vol. 134. P. 382–389. doi: 10.1192/bjp.134.4.382

[33] Finlay AY, Khan GK. Dermatology life quality index (DLQI): A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x

[34] Finlay A.Y., Khan G.K. Dermatology life quality index (DLQI): A simple practical measure for routine clinical use // Clin Exp Dermatol. 1994. Vol. 19, N 3. P. 210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x

[35] Mina S, Jabeen M, Singh S, Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J Dermatol. 2015;60(2):211. doi: 10.4103/0019-5154.152564

[36] Mina S., Jabeen M., Singh S., Verma R. Gender differences in depression and anxiety among atopic dermatitis patients // Indian J Dermatol. 2015. Vol. 60, N 2. P. 211. doi: 10.4103/0019-5154.152564

[37] Khan SM, Shaikh MA, Ali MZ. Depression in common dermatological patients attending outpatient department. KYAMC J. 2012;2(2):164–171. doi: 10.3329/kyamcj.v2i2.13260

[38] Khan S.M., Shaikh M.A., Ali M.Z. Depression in common dermatological patients attending outpatient department // KYAMC J. 2012. Vol. 2, N 2. P. 164–171. doi: 10.3329/kyamcj.v2i2.13260

[39] Hussain S, Ronaldson A, de la Torre AJ, et al. Depressive and anxiety symptomatology among people with asthma or atopic dermatitis: A population-based investigation using the UK Biobank data. Brain Behav Immun. 2020;90:138–144. doi: 10.1016/j.bbi.2020.08.003

[40] Hussain S., Ronaldson A., de la Torre A.J., et al. Depressive and anxiety symptomatology among people with asthma or atopic dermatitis: A population-based investigation using the UK Biobank data // Brain Behav Immun. 2020. Vol. 90. P. 138–144. doi: 10.1016/j.bbi.2020.08.003

[41] Kage P, Poblotzki L, Zeynalova S, et al. Depression, anxiety, and suicidal ideation in patients with atopic eczema in a prospective study in Leipzig, Germany. Int Arch Allergy Immunol. 2022;183(4):409–414. EDN: UORCSS doi: 10.1159/000520159

[42] Kage P., Poblotzki L., Zeynalova S., et al. Depression, anxiety, and suicidal ideation in patients with atopic eczema in a prospective study in Leipzig, Germany // Int Arch Allergy Immunol. 2022. Vol. 183, N 4. P. 409–414. EDN: UORCSS doi: 10.1159/000520159

[43] Vinh NM, Trang VT, Dac Thuy LN, et al. The anxiety and depression disorder in adults with atopic dermatitis: Experience of a dermatology hospital. Dermatol Reports. 2022;15(1):9524. EDN: MGZFCD doi: 10.4081/dr.2022.9524

[44] Vinh N.M., Trang V.T., Dac Thuy L.N., et al. The anxiety and depression disorder in adults with atopic dermatitis: Experience of a dermatology hospital // Dermatol Reports. 2022. Vol. 15, N 1. P. 9524. EDN: MGZFCD doi: 10.4081/dr.2022.9524

[45] Zalewski A, Krajewski PK, Szepietowski JC. Psychosocial consequences of hand eczema: A prospective cross-sectional study. J Clin Med. 2023;12(17):5741. EDN: HPYFZM doi: 10.3390/jcm12175741

[46] Zalewski A., Krajewski P.K., Szepietowski J.C. Psychosocial consequences of hand eczema: A prospective cross-sectional study // J Clin Med. 2023. Vol. 12, N 17. P. 5741. EDN: HPYFZM doi: 10.3390/jcm12175741

[47] Long Q, Jin H, You X, et al. Eczema is a shared risk factor for anxiety and depression: A meta-analysis and systematic review. PLoS One. 2022;17(2):e0263334. doi: 10.1371/journal.pone.0263334

[48] Long Q., Jin H., You X., et al. Eczema is a shared risk factor for anxiety and depression: A meta-analysis and systematic review // PLoS One. 2022. Vol. 17, N 2. P. e0263334. doi: 10.1371/journal.pone.0263334

[49] Adesanya EI, Matthewman J, Schonmann Y, et al. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: A systematic review and meta-analysis. Br J Dermatol. 2023;188(4):460–470. doi: 10.1093/bjd/ljac132

[50] Adesanya E.I., Matthewman J., Schonmann Y., et al. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: A systematic review and meta-analysis // Br J Dermatol. 2023. Vol. 188, N 4. P. 460–470. doi: 10.1093/bjd/ljac132

[51] DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–2107. doi: 10.1001/archinte.160.14.2101

[52] DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence // Arch Intern Med. 2000. Vol. 160, N 14. P. 2101–2107. doi: 10.1001/archinte.160.14.2101

[53] Oh SH, Bae BG, Park CO et al. Association of stress with symptoms of atopic dermatitis. Acta Derm Venereol. 2010;90(6):582–588. doi: 10.2340/00015555-0933

[54] Oh S.H., Bae B.G., Park C.O., et al. Association of stress with symptoms of atopic dermatitis // Acta Derm Venereol. 2010. Vol. 90, N 6. P. 582–588. doi: 10.2340/00015555-0933

[55] Ong PY. Atopic dermatitis: Is innate or adaptive immunity in control? A clinical perspective. Front Immunol. 2022;13:943640. doi: 10.3389/fimmu.2022.943640

[56] Ong P.Y. Atopic dermatitis: Is innate or adaptive immunity in control? A clinical perspective // Front Immunol. 2022. Vol. 13. P. 943640. doi: 10.3389/fimmu.2022.943640

[57] Choy DF, Hsu DK, Seshasayee D, et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol. 2012;130(6):1335–1343.e5. doi: 10.1016/j.jaci.2012.06.044

[58] Choy D.F., Hsu D.K., Seshasayee D., et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation // J Allergy Clin Immunol. 2012. Vol. 130, N 6. P. 1335–1343.e5. doi: 10.1016/j.jaci.2012.06.044

[59] Lopatnikova JA, Alshevskaya AA, Krugleeva OL, et al. Expression of TNFα receptors on immunocompetent cells is increased in atopic dermatitis. Int Arch Allergy Immunol. 2017;174(3-4):151–160. doi: 10.1159/000481135

[60] Lopatnikova J.A., Alshevskaya A.A., Krugleeva O.L., et al. Expression of TNFα receptors on immunocompetent cells is increased in atopic dermatitis // Int Arch Allergy Immunol. 2017. Vol. 174, N 3-4. P. 151–160. doi: 10.1159/000481135

RIGHTS & PERMISSIONS

Eco-Vector